Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119467 | 1.00 | NR1H2 (0.32) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL874863 | 1.00 | NR1H2 (0.32) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL875468 | 0.87 | HSD17B10 (0.34) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL15719896 | 0.86 | — | — | |
| SCHEMBL24411297 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL29819835 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL2954122 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL375503 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL5560650 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 | |
| SCHEMBL820473 | 0.81 | EPHX1 (0.36) | NR1H2NR1H3PTPN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | NR1H2 2556/4885NR1H3 2349/4885PTPN1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.